Benefits at 5 years of routine invasive strategy in Non-ST-Elevation Acute Coronary Syndromes

Original title: Impact of an invasive strategy on five years outcomein men and women with Non-ST-Elevation Acute Coronary Syndromes. Reference: Joakim Alfredsson et al. Am Heart J. 2014;Epub ahead of print.

 

This meta-analysis included patients with non-ST-elevation acute coronary syndrome (NSTE ACS) from randomized studies FRISC II, ICTUS and RITA 3 and compared the routine invasive strategy (n=2721) with coronary catheterization and, when possible, angioplasty or surgery vs. a more selective strategy (n=2746) consisting of initial stabilization with medical therapy, leaving coronary catheterization for patients with recurrent ischemia symptoms despite medical treatment, hemodynamically unstable, or showing signs of ischemia on a stress test. 

Women represented one third of overall cohort (n=1751), were of older age, smoked less and had higher hypertension rates than men. On the other hand, men often had a history of MI and revascularization.

After a 5 year follow up, routine invasive strategy in men reduced primary end point of cardiovascular death or AMI (15.6% vs 19.8%; p=0.01), and individual components, cardiovascular death (6.6% vs 8,7%; p=0.07) and AMI (10.8% vs 14.6%; p=0.01). These same points saw no significant change in women.

In the light of a risk stratified analysis, men presenting medium or high risk non ST elevation AMI at baseline, saw benefit from the routine invasive strategy. On the contrary, women in all risk subgroups saw a similar prognosis, regardless of treatment strategy. 

Conclusion

This meta-analysis based in three large randomized studies on non ST elevation AMI confirmed the long term benefit of routine invasive strategy in men, while women saw no significant benefit.

Editorial Comment

Subgroup analysis, especially if not pre specified by protocol, must be interpreted with caution. Even in this large dataset, the number of events in women was low and the difference between men and women could be the result of weak statistical power in women.

Among randomized patients undergoing routine invasive strategy, women often lack significant lesions (28.2% vs 9.3%) and are less likely to have 3 vessel lesions (21.1% vs 30.6%). 

To conclude, women had less severe coronary disease and this may have reduced the benefit of a routine invasive strategy. Today, guidelines have no specific recommendation as regards gender for non ST elevation AMI syndromes. 

SOLACI.ORG

More articles by this author

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...